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Abstract
Background: The surface antigen PfEMP-1 is a key virulence factor of the human malaria parasite implicated in the
cytoadherence of Plasmodium falciparum infected erythrocytes to a range of receptors on host endothelium.
Among these host receptors, binding to ICAM-1 is related to cerebral malaria. The majority of the mortality in
children with cerebral malaria is seen within 24 h of hospital admission despite the use of effective anti-parasite
drugs, therefore, the development of adjunctive therapies is urgently needed.
The polyphenolic compound (+)-epigallocatechin gallate ((+)-EGCG) has been previously evaluated for anti-
adhesive properties using a small number of laboratory parasite isolates. Here, this property is further explored
using a new panel of ICAM-1-binding patient isolates of P. falciparum to ascertain if (+)-EGCG might be effective as
a broad spectrum inhibitor of ICAM-1-based cytoadherence.
Methods: Plasmodium falciparum lines, including A4 and ItG as positive controls and nine new ICAM-1 binding
patient isolates, were allowed to bind with ICAM-1-Fc protein under static assay conditions in the presence and
absence of 50 μM (+)-EGCG. Adhesion levels of all the parasite strains were quantified by microscopy as the mean
number of infected erythrocyte (IE) bound per mm
2 of surface area and statistical comparisons were made to
demonstrate the effect of (+)-EGCG on the binding of various parasite variants to human ICAM-1.
Results: This study revealed that binding of patient isolates to ICAM-1 was reduced significantly with inhibition
levels of 37% in patient isolate BC-12 up to a maximum of 80% in patient isolate 8146 at 50 μM (+)-EGCG.
Conclusion: Evaluation of the anti-adhesive property of (+)-EGCG against a new panel of ICAM-1-binding patient
isolates of P. falciparum showed that this inhibitor, identified as potential mimic of the L43 loop of human ICAM-1,
was effective at blocking cytoadherence.
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Background
Plasmodium falciparum malaria remains a major life-threa-
tening parasitic disease, killing approximately 1 million peo-
ple each year worldwide, mainly in sub-Saharan Africa [1].
Children and pregnant women are most susceptible. This
infection can progress unpredictably to severe forms,
including anaemia and cerebral malaria. The surface anti-
gen PfEMP-1 (P. falciparum erythrocyte membrane pro-
tein-1) is a key virulence factor of the human malaria
parasite, encoded by about 60 var genes per haploid gen-
ome [2]. PfEMP-1 variants have been implicated in the
cytoadherence of P. falciparum-infected erythrocytes (IEs)
to several binding receptors on host vascular endothelium
[3-5], sequestering infected cells away from the spleen,
which would otherwise destroy them. Switching of var
gene expression allows the parasite to modify the antigenic
and functional properties of IEs, thereby evading immunity
and affecting infection outcome. In most cases the parasite
expresses a single var gene at a time, maintaining all other
members of the family in a transcriptionally silent state [6].
Among the many host receptors, binding to Intercellular
Adhesion Molecule -1 (ICAM-1) has been shown to be
related to cerebral malaria [7]. The majority of the mortal-
ity with cerebral malaria is seen within 24 h of hospital
admission despite the use of effective anti-parasite drugs
[8], therefore, the development of adjunctive therapies is
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locatechin gallate ((+)-EGCG) has been shown to have
anti-adhesive properties [9]. This compound was identified
using in silico molecular alignment techniques based on
DE loop of human ICAM-1, which is a common feature of
the ICAM-1 binding sites for at least the three P. falci-
parum laboratory variants tested [10]. (+)-EGCG inhibited
binding of two variant ICAM-1 binding parasite lines at
micromolar concentrations in a highly specific, dose-
dependent manner. Interestingly, binding to CD36 was
partially inhibited by EGCG in an ICAM-1-binding line,
but not in a laboratory isolate that showed no binding to
ICAM-1. In this current study the anti-adhesive properties
of (+)-EGCG were measured against a new panel of
ICAM-1-binding patient isolates of P. falciparum in order
to evaluate the breadth of the cytoadherence inhibitory
effect.
Methods
Recombinant protein and cytoadherence inhibitor
(+)-EGCG, which is known to show anti-cytoadherence
properties with A4 and ItG parasite strains, was used at
50 μM concentration. The purified receptor protein
used in this study was human ICAM-1-Fc, which was
prepared as previously described [11].
ICAM-1 selection of parasite lines using Dynabeads
50 μl Protein A Dynabeads (Invitrogen) were washed 3
times with 500 μl PBS/1% BSA and then resuspended in
100 μlP B S / 1 % B S A .2 . 5μg ICAM-1-Fc protein was
added to the bead suspension and made up to 400 μlb y
adding PBS/1%BSA. This was then incubated at room
temperature by rotating for 1 h, again washed with 500
μl PBS/1% BSA using a magnet to retain the beads each
time. Beads were resuspended in 200 μlP B S / 1 %B S A
and stored at 4°C overnight.
Parasite culture was enriched for trophozoite stages
using Plasmion by standard protocols [12]. 50 μl of Plas-
mion enriched parasites and 150 μlP B S / 1 %B S Aw e r e
added to previously prepared ICAM-1 labelled Dynabeads.
The mixture was incubated at room temperature, rotating
for 45 min then gently washed twice with 500 μl PBS/1%
BSA using a magnet to retain the beads each time. Beads
were resuspended in parasite media and cultured with
fresh washed red blood cells (RBCs).
Parasite culture
Plasmodium falciparum lines used in this study were the
laboratory lines A4 and ItG, as a positive controls, and
patient isolates PO-69, PCM-7, GL-6, BC-31, BC-12,
8206, 8146, 8131, 6392, which have previously been
selected for binding to ICAM-1. Separate experiments
had shown, using mutant ICAM-1 proteins, that all the
ICAM-1-binding isolates used in this study have the L43
loop of ICAM-1 as a critical part of their binding site. To
minimize the effect of antigenic switching in vitro the
selected parasite lines were maintained in culture for not
more than 3 weeks post-selection. RBCs for parasite cul-
ture were purified away from mononuclear cells and
granulocytes using Lymphoprep.
Parasites were grown to maturity for 24-48 h from
frozen stabilates. Laboratory parasite lines and parasites
from patient isolates were cultured at 1% haematocrit in
group O human erythrocytes using standard culturing
techniques, using RPMI 1640 medium (supplemented
with 37.5 mM HEPES, 7 mM D-glucose, 6 mM NaOH,
40 μg gentamicin sulfate/ml, 2 mM L-glutamine, and
10% human serum) at a pH of 7.2 in a gas mixture of
96% nitrogen, 3% carbon dioxide, and 1% oxygen. The
parasitaemia was calculated by determination of the
number of IEs per 500 red blood cells (RBC) for thin
blood films. Baseline RBC counts were used to calculate
the parasite density (parasites/μl). For all adhesion assays
the IE suspension was adjusted to 3% parasitaemia and
1% haematocrit.
Static adhesion assays
Purified recombinant ICAM-1-Fc protein and PBS only
(as negative control) were spotted in triplicate in a radial
pattern using 2 μl spots on 60 × 50 mm bacteriological
plastic Petri dishes (Falcon 1007; Becton Dickinson,
Oxford, UK) at concentrations of 50 μg/ml for ICAM-1.
This concentration had previously been shown to be
within the dynamic range for detecting differences in
adhesion and produce coated surfaces with receptors at
levels approximately equal to receptor densities seen on
activated endothelium [13]. The dishes were placed in a
humidified chamber for 2 h at 37°C to allow the proteins
to adsorb to the surface of Petri dish, after which the pro-
tein solution and PBS were aspirated off and the
uncoated plastic area was blocked overnight with 1%
BSA/PBS at 4°C. The plates were warmed at 37°C for one
hour, blocking solution (1% BSA/PBS) was removed and
plates were washed with binding buffer (RPMI 1640 with
0.2% glucose) prior to adding 1.5 ml of parasite culture
(3% parasitaemia; 1% haematocrit in binding medium),
with and without 50 μM (+)-EGCG. The plates were
incubated at 37°C for one hour with gentle resuspension
every 10 min. Unbound infected and uninfected erythro-
cytes were removed by gentle manual washing (4-6
washes) with 2 ml binding medium per wash (monitoring
of adhered cells was performed using an inverted micro-
scope). The adhered IEs were fixed with 1% glutaralde-
hyde in phosphate buffered saline for 1 h and stained
with 10% Giemsa for 30 min. Adhesion levels of all para-
site strains (with and without (+)-EGCG) were quantified
by microscopy using a unique, anonymous identifier for
each dish (with the operator blinded to the IE category)
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bound per mm
2 of surface area. Inhibition experiments
were conducted twice for isolates PO-69, 8206 and 8131,
and three times for the other parasite lines. The results
were compared to quantify the effect of (+)-EGCG on
binding of various ICAM-1-binding patient isolates to
human ICAM-1.
Results and discussion
This study focussed on the ability of the naturally occur-
ring polyphenolic compound (+)-EGCG to inhibit the
binding of various patient isolates to ICAM-1. All the iso-
lates tested showed significantly reduced adhesion with
inhibition ranging from 37%-80% (Figure 1). This varying
degree of inhibition of various patient isolates by
(+)-EGCG, may refer to variable contact residues on
PfE M P - 1o fd i f f e r e n tp a t i e n ti s o l a t e si n v o l v e di nt h e
binding with ICAM-1 as seen in previous studies [10].
On the basis of these results it can be concluded that,
despite the variation in the contact residues engaged on
the BED side of ICAM-1 by different PfEMP-1 variants
[14], some structural similarity is retained. It seems likely
that the L-43 loop of human ICAM-1 is a key domain in
the interaction with PfEMP-1 based on the observation
that the whole set of ICAM-1 binding patient isolates
was inhibited by (+)-EGCG, which is known to mimic
L-43 loop of ICAM-1. Although several other binding
activities use the N-terminal domain of ICAM-1 (e.g.
T-cells, rhinovirus, fibrinogen), the L43 loop appears to
be unique to P. falciparum-infected erythrocytes, sup-
porting its use as a starting point for the design of speci-
fic inhibitors of cytoadherence. However, there are still a
number of issues that still need to be resolved before
taking (+)-EGCG further, such as its ability to reverse
existing cytoadherence rather than just inhibition of new
binding and testing the compound for disruption of
ICAM-1-dependent IE binding in the context of endothe-
lial cells. Also, to improve the pharmacological character-
istics of (+)-EGCG, it is necessary to ‘remake’ the
chemical scaffold to produce a lead structure that is
more amenable to chemical synthesis. These experiments
are underway.
Conclusions
(+)-EGCG is able to inhibit binding to ICAM-1 by a
range of patient-derived parasite isolates. This supports
further development of anti-adhesive compounds with
broad reactivity based on this chemical scaffold as novel
adjunct therapies for cerebral malaria.
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Figure 1 Screening of (+)-EGCG against new ICAM-1 binding
patient isolates of P. falciparum. EGCG was used at 50 μM
concentration during the binding assays. Results are shown as mean
inhibition (compared to no inhibitor control) ± standard deviation.
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